难治性子宫腺肉瘤1例

doi:10.3760/cma.j.issn.1007-1245.2024.03.031

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (3): 503-507.DOI: 10.3760/cma.j.issn.1007-1245.2024.03.031

难治性子宫腺肉瘤1例

时娟娟杜超李南韩珊珊崔秀娟

济宁医学院附属滕州市中心人民医院妇科，滕州　277599

收稿日期:2023-08-10 出版日期:2024-02-01 发布日期:2024-03-07
通讯作者: 崔秀娟，Email：zhaoyi_2005@163.com
基金资助:
山东省医药卫生科技项目（202305010638）；济宁医学院2022年度实践教学教育研究计划（JYSJ2022B49）；滕州市中心人民医院“扬帆”计划院级科研立项项目（202302）；枣庄市科技发展计划项目（2023NS38）

One case of refractory adenosarcoma of uterus

Shi Juanjuan, Du Chao, Li Nan, Han Shanshan, Cui Xiujuan

Department of Gynecology, Tengzhou Central People's Hospital, Tengzhou 277599, China

Received:2023-08-10 Online:2024-02-01 Published:2024-03-07
Contact: Cui Xiujuan, Email: zhaoyi-2005@163.com
Supported by:
Shandong Medicine and Health Technology Project (202305010638);Practical Teaching Education Research Program of Jining Medical University in 2022 (JYSJ2022B49); Scientific Research Project of Sailing Plan of Tengzhou Central People's Hospital (202302);Zaozhuang Science and Technology Development Plan Project (2023NS38)

摘要/Abstract

摘要：

子宫腺肉瘤被认为低度恶性子宫肿瘤。子宫腺肉瘤发病率低，缺乏特异性临床表现及实验室和影像学检查，大部分子宫腺肉瘤患者预后较好。本文报道1例难治性子宫腺肉瘤患者术后迅速出现转移并致死亡的诊疗经过，以提高临床医师对该疾病的认识并作出个性化处理。

关键词:

子宫腺肉瘤, 转移, 预后, 死亡

Abstract:

Adenosarcoma of uterus is considered to be a low grade malignant uterine tumor. It has a low incidence and lacks specific clinical manifestations and laboratory and radiographic examinations. Most patients with adenosarcoma of uterus have good prognosis. This paper reports the diagnosis and treatment of a patient with refractory adenosarcoma of uterus who had metastasis rapidly and died after surgery, so as to improve the clinicians' understanding about this disease and take individualized treatment.

Key words:

Adenosarcoma of uterus, Metastasis, Prognosis, Death

时娟娟杜超李南韩珊珊崔秀娟.

难治性子宫腺肉瘤1例 [J]. 国际医药卫生导报, 2024, 30(3): 503-507.

Shi Juanjuan, Du Chao, Li Nan, Han Shanshan, Cui Xiujuan.

One case of refractory adenosarcoma of uterus [J]. International Medicine and Health Guidance News, 2024, 30(3): 503-507.

参考文献

[1] 梁金晓,林仲秋.«FIGO2018癌症报告»——子宫肉瘤诊治指南解读[J].中国实用妇科与产科杂志,2018,34(12):1366-1371.DOI:10.19538/j.fk2018120116.
[2] Hodgson A, Amemiya Y, Seth A, et al. High-grade müllerian adenosarcoma: genomic and clinicopathologic characterization of a distinct neoplasm with prevalent TP53 pathway alterations and aggressive behavior[J]. Am J Surg Pathol, 2017,41(11):1513-1522. DOI: 10.1097/PAS.0000000000000907.
[3] Nathenson MJ, Conley AP. Prognostic factors for uterine adenosarcoma: a review[J]. Expert Rev Anticancer Ther, 2018,18(11):1093-1100. DOI: 10.1080/14737140.2018. 1518136.
[4] Ulrich UA, Denschlag D. Uterine adenosarcoma[J]. Oncol Res Treat, 2018,41(11):693-696. DOI: 10.1159/000494067.
[5] Ghartimagar D, Shrestha B, Ghosh A, et al. Adenosarcoma of uterus- rare biphasic malignant tumor: a case report[J]. JNMA J Nepal Med Assoc, 2021,59(234):200-203. DOI: 10.31729/jnma.5373.
[6] Zhang Y, Li Y, Huang H, et al. Low-grade endometrial stromal sarcoma and uterine adenosarcoma: a comparison of clinical manifestations and outcomes[J]. J Cancer, 2019,10(15):3352-3360. DOI: 10.7150/jca.30691.
[7] 陈思蕾,王光伟,赵万成,等.子宫肉瘤的术前诊断[J].国际生殖健康/计划生育杂志,2019,38(3):257-260.DOI:10.3969/j.issn.1674-1889.2019.03.019.
[8] Wais M, Tepperman E, Bernardini MQ, et al. A multicentre retrospective review of clinical characteristics of uterine sarcoma[J]. J Obstet Gynaecol Can, 2017,39(8):652-658. DOI: 10.1016/j.jogc.2017.03.090.
[9] Mallmann P. Uterine sarcoma - difficult to diagnose, hard to treat[J]. Oncol Res Treat, 2018,41(11):674. DOI: 10.1159/000494393.
[10] Dossi R, Frapolli R, Di Giandomenico S, et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1[J]. Int J Cancer, 2015,136(3):721-729. DOI: 10.1002/ijc.29023.
[11] Nagai T, Takai Y, Akahori T, et al. Novel uterine sarcoma preoperative diagnosis score predicts the need for surgery in patients presenting with a uterine mass[J]. Springerplus, 2014,3:678. DOI: 10.1186/2193-1801-3-678.
[12] Visnovsky J, Kudela E, Slavik P, et al. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II[J]. Neuro Endocrinol Lett, 2015,36(8):750-757.
[13] Song KJ, Yu XN, Lv T, et al. Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma[J]. Medicine (Baltimore), 2018,97(14):e0268. DOI: 10.1097/MD.0000000000010268.
[14] Shah SH, Jagannathan JP, Krajewski K, et al. Uterine sarcomas: then and now[J]. AJR Am J Roentgenol, 2012,199(1):213-223. DOI: 10.2214/AJR.11.7287.
[15] Nathenson MJ, Ravi V, Fleming N, et al. Uterine adenosarcoma: a review[J]. Curr Oncol Rep, 2016,18(11):68. DOI: 10.1007/s11912-016-0552-7.
[16] 谢玲玲,林荣春,林仲秋.«2021 NCCN子宫肿瘤临床实践指南(第1版)»解读[J].中国实用妇科与产科杂志,2021,37(1):75-81.DOI:10.19538/j.fk2021010119.
[17] Nathenson MJ, Conley AP, Lin H, et al. The importance of lymphovascular invasion in uterine adenosarcomas: analysis of clinical, prognostic, and treatment outcomes[J]. Int J Gynecol Cancer, 2018,28(7):1297-1310. DOI: 10.1097/IGC.0000000000001306.
[18] Machida H, Nathenson MJ, Takiuchi T, et al. Significance of lymph node metastasis on survival of women with uterine adenosarcoma[J]. Gynecol Oncol, 2017,144(3):524-530. DOI: 10.1016/j.ygyno.2017.01.012.
[19] Denschlag D, Thiel FC, Ackermann S, et al. Sarcoma of the uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015) [J]. Geburtshilfe Frauenheilkd, 2015,75(10):1028-1042. DOI: 10.1055/s-0035-1558120.
[20] Agarwal R, Rajanbabu A, Nair IR, et al. Endometrial stromal sarcoma-a retropsective analysis of factors affecting recurrence[J]. Eur J Obstet Gynecol Reprod Biol, 2017,216:92-97. DOI: 10.1016/j.ejogrb.2017.07.011.
[21] Si M, Jia L, Song K, et al. Role of lymphadenectomy for uterine sarcoma: a meta-analysis[J]. Int J Gynecol Cancer, 2017,27(1):109-116. DOI: 10.1097/IGC.0000000000000842.
[22] Hu H, Wei Z, Zhao H, et al. Epidemiology of adenosarcoma and the inverse probability of treatment weighting (IPTW) adjusted survival analysis of lymph node dissection in uterine adenosarcoma[J]. Medicine (Baltimore), 2022,101(38):e30607. DOI: 10.1097/MD.0000000000030607.
[23] Nathenson MJ, Conley AP, Lin H, et al. Treatment of recurrent or metastatic uterine adenosarcoma[J]. Sarcoma, 2017,2017:4680273. DOI: 10.1155/2017/4680273.
[24] Carroll A, Ramirez PT, Westin SN, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence[J]. Gynecol Oncol, 2014,135(3):455-461. DOI: 10.1016/j.ygyno.2014.10.022.
[25] Yuan Z, Shen K, Yang J, et al. Uterine adenosarcoma: a retrospective 12-year single-center study[J]. Front Oncol, 2019,9:237. DOI: 10.3389/fonc.2019.00237.
[26] Tate K, Watanabe R, Yoshida H, et al. Uterine adenosarcoma in Japan: clinicopathologic features, diagnosis and management[J]. Asia Pac J Clin Oncol, 2018,14(4):318-325. DOI: 10.1111/ajco.12859.
[27] Yuan Z, Cao D, Yu M, et al. Uterine and cervical adenosarcoma: a retrospective study of overall oncologic outcomes and fertility preservation in early-stage disease[J]. Oncologist, 2019,24(9):e870-e879. DOI: 10.1634/theoncologist.2018-0791.
[28] Plentz TBSF, Candido EC, Dias LF, et al. Diagnosis, treatment and survival of uterine sarcoma: a retrospective cohort study of 122 cases[J]. Mol Clin Oncol, 2020,13(6):81. DOI: 10.3892/mco.2020.2151.

难治性子宫腺肉瘤1例

One case of refractory adenosarcoma of uterus

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	于潇杰程立浩张浩张浩杰杨振林. 铁死亡与乳腺癌患者化疗耐药的关系研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 353-356.
[2]	刘茗刘帅张楠. 早期乳腺癌患者保乳术后免除放疗的研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 357-362.
[3]	刘允邵长生宋远征刘志杨锡明. 初始样本转移技术在老年骨折患者血培养采血中的应用效果分析 [J]. 国际医药卫生导报, 2024, 30(3): 493-498.
[4]	崔玉霞杜冰高风双. 慢性疾病轨迹框架下自我护理模式对老年胃癌切除术患者的效果影响 [J]. 国际医药卫生导报, 2024, 30(3): 524-528.
[5]	罗晓洁王巍巍王怡萌王峪. 脓毒症相关急性呼吸窘迫综合征患者28 d死亡的无创预测研究 [J]. 国际医药卫生导报, 2024, 30(2): 263-268.
[6]	王新颖. 硝普钠对高血压危象患者临床体征及预后情况的影响 [J]. 国际医药卫生导报, 2024, 30(2): 284-288.
[7]	姜军选方圆. 补中益气汤在驱动基因阴性NSCLC免疫治疗中的应用价值 [J]. 国际医药卫生导报, 2024, 30(2): 305-309.
[8]	冯南凯. 超声引导下局部综合介入疗法治疗大肝癌患者的效果 [J]. 国际医药卫生导报, 2024, 30(1): 62-66.
[9]	蔡荣丹刘建帅冯俊霞张云芳刘云启王雅宁. 铁死亡在糖尿病肾病中的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1193-1197.
[10]	詹泽宇林思恩魏波. 骨肉瘤临床治疗现状与创新疗法研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1197-1200..
[11]	侯长冉姜京汝花义同. 软骨素聚合因子在乳腺癌中的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1201-1204.
[12]	石婉莹程国振杜兴俊. 硫酸羟氯喹、地塞米松、转移因子治疗口腔扁平苔藓的临床效果 [J]. 国际医药卫生导报, 2023, 29(8): 1090-1094.
[13]	张琪赵燕超. 奥美拉唑注射液联合肠内营养支持治疗急性胰腺炎患者的效果 [J]. 国际医药卫生导报, 2023, 29(7): 978-982.
[14]	袁法伟李炳奇. 体外膜肺氧合治疗呼吸衰竭的效果及预后分析 [J]. 国际医药卫生导报, 2023, 29(7): 973-977.
[15]	吴绍惠肖颖秀杨丹晓彭海聪黄晓新. 同型半胱氨酸及胱抑素C对急性脑梗死患者静脉溶栓的疗效影响 [J]. 国际医药卫生导报, 2023, 29(6): 813-817.